REBUILD-SM Trial

Disease target: Interstitial Lung Disease

Recruitment target: 400 participants

Duration: Intervention period of 12 weeks, with follow-up at 26 and 52 weeks.

What is involved?

This study aims to determine if giving people with ILD the tools and support to improve their self-management skills will improve their quality of life, reduce anxiety and depression, and increase physical activity levels and sense of autonomy.

It will also investigate if the intervention will reduce the cost and burden of managing ILD for patients and the healthcare system and be readily implementable.

Investigational medicinal product, comparator and randomisation

• The intervention group will have access to web-based learning modules and support from a self-management clinician, who will engage with the participant four times during the study via phone or video call.
• The comparator is standard of care and a reduced functionality version of the app. Patients in the control group will also receive phone calls at the same frequency to control for the effects of attention.
• Randomisation will be in a 1:1 allocation (intervention vs control) and will be stratified for FVC (51% or more; 50% or less); site; and diagnosis (IPF or other).

Can I participate?

If you would like to take part or have any questions about this research study, please complete our Patient Trial Enquiry Form or email enquiries@pactnetwork.com.au.

This study is sponsored by The University of Sydney.

Clinicaltrials.gov ID: NCT06122233